


**BioVendor
Group**

MBA

Microblot- Array

Multiplex diagnostics
in microtiter plate format

ENG



Definition of efficient multiplex diagnostics

Microblot-Array is an immunoblot array in microtiter plate format designed for efficient multiplex diagnostics. The technology eliminates the bottleneck of traditional BLOT processing and capacity and opens up the way to high throughput testing and automation.




The comprehensive evaluation of Microblot Array testing is ensured by using the Microblot-Array Software in combination with the Microblot-Array Reader, enabling complex image analysis including results evaluation and connectivity to LIS.

Main clinical areas covered

- Infectious serology
- Autoimmunity

Microblot-Array principle

Specific recombinant proteins/antigens spotted onto a nitrocellulose membrane



- **R** - Reference
- **TC** - Test control
- **CA** - Conjugate control IgA
- **CG** - Conjugate control IgG
- **CM** - Conjugate control IgM
- **C1** - Calibration 1
- **C2** - Calibration 2
- **C3** - Calibration 3
- **C4** - Calibration 4


Complex solution

Microblot-Array Software

- Automated test identification
- Intuitive and user-friendly guiding throughout the results evaluation
- Complex image analysis
- Optional manual control of spot localization
- Detailed results comparison within single wells and spots
- Evaluation of the validity test through control spots
- Export of results in various formats
- LIS connectivity

Calibration data

- Innovative processing and evaluation with LOT identification
- Calibration data ensure significant benefits:
 - Interchangeability of conjugate and substrate between the same Ig classes
 - Unification of evaluation criteria for all MBA kits
 - The more effective automatic processing



Microblot-Array

- Antigens spotted in triplicate – minimizing statistical variation
- Controls in each well
- 4 calibration spots to create a calibration curve
- Evaluation based on combination of positive antigen spots: qualitative, quantitative (U/ml) or semiquantitative (IP)

Microblot-Array Reader

- Fast high-quality scanning and evaluation: 5 min. per full plate
- Scanning of selected wells
- Automated spot localization and image analysis
- Optimized for a 96-well microtiter plates format



Benefits

Efficiency

- Analysis of up to 96 patient samples per plate
- Low sample consumption - 10 μ l
- Parallel testing of multiple markers simultaneously
- Time and cost saving diagnostics

Flexibility


- One parameter x various parameters
- One well x high number of samples
- Manual processing x automated processing

Automation

- Possibility of automated processing using an ELISA instrument
- Intuitive software for test evaluation
- Evaluation of individual antigens and their association with pathogen species or disease type

User comfort


- Ready-to-use components
- Identical assay procedure (30-30-15 min.)
- Remote troubleshooting
- Reagents interchangeability due to batch identification (calibration data)




Automatic processing by ELISA analyzer minimizes hands-on time, eliminates errors rate due to the QR code identification system, and improves the throughput of samples.

Protocol Summary


Step No.	Test steps
	1. Pipette Universal Solution – 150 µl
	2. Wells soaking at room temperature for 10 min.
	3. Aspirate off
	4. Dilute samples serum/plasma 1:51 (10 µl + 500 µl) cerebrospinal fluid 1:3 (50 µl + 100 µl) synovial fluid 1:17.5 (10 µl + 165 µl)
	5. Pipette control and diluted samples – 100 µl
	6. Incubate at room temperature for 30 min.
	7. Quick wash using the Universal Solution
	8. Aspirate and wash 3 × 5 min. with 150 µl of Universal Solution
	9. Pipette Conjugate – 100 µl
	10. Incubate at room temperature for 30 min.
	11. Quick wash using the Universal Solution
	12. Aspirate and wash 3 × 5 min. with 150 µl of Universal Solution
	13. Pipette Substrate Solution (BCIP/NBT) – 100 µl
	14. Incubate at room temperature for 15 min.
	15. Quick wash using the distilled water
	16. Aspirate and wash 2 × 5 min. with 200 µl of distilled water
	17. Dry and evaluate strips





Microblot-Array for the diagnostics of systemic autoimmune diseases

The main benefit of Microblot-Array ANA kits is the high number of antigens which can be simultaneously detected in one sample. The kits are primarily intended for confirmation of ELISA or other screening method. However, they also enable identification of specific antibody and thus differentiation of systemic autoimmune diseases, such as myositis, scleroderma, systemic lupus and others. The kits are optimized and validated for detection of specific IgG in human serum or plasma.



Test Characteristics


Parameters of the Microblot-Array ANA kit

	Diagnostic Sensitivity	Diagnostic Specificity
ANA	95.2% (n = 398)	95.3% (n = 148)

Comparative Study – Correlation of Results


Myopathy

n = 80	Microblot-Array	BLOT
positive	70	69
negative	0	0
total conformity	98.6 %	




Systemic sclerosis

n = 124	Microblot-Array	BLOT
positive	107	106
negative	0	0
total conformity	99.1 %	



n = 204	Microblot-Array	ELISA
positive	194	186
negative	7	0
total conformity	95.5 %	



■ conformity ■ disagreement

Spot No.	Antigen	Description	Probable association with disease (Evaluation of association with disease by SW)			
			ANA	Myositis	Scleroderma	SLE and other connective tissue diseases
A1	Jo-1	Hystidyl tRNA synthetase	●	●		
A2	PL-7	Threonyl tRNA synthetase	●	●		
A3	PL-12	Alanyl tRNA synthetase	●	●		
A4	EJ	Glycyl tRNA Synthetase	●	●		
A5	OJ	Isoleucyl tRNA synthetase	●	●		
A6	KS	Asparaginyl tRNA synthetase	●	●		
A7	YARS	Tyrosyl tRNA synthetase (Ha)	●	●		
A8	ZoA	Phenylalanyl tRNA synthetase	●	●		
A9	ZoB	Phenylalanyl tRNA synthetase	●	●		
A10	HMGCR*	3-hydroxy-3methylglutaryl-coenzyme A reductase	●	●		
A11	SAE-1	Small ubiquitin-like modifier activating enzyme	●	●		
A12	SAE-2	Small ubiquitin-like modifier activating enzyme	●	●		
A13	SRP54	Signal recognition particle	●	●		
A14	Mi-2	Helicase protein-nuclear transcription	●	●		
A15	TIF1γ	Transcription Intermediary Factor 1	●	●		
A16	MDA5	Melanoma differentiation associated protein 5 (CADM-140)	●	●		
A17	NXP2	Nuclear matrix protein 2 (p140, MJ)	●	●		
A18	PMScl 100	Human exosome complex	●	●	●	
A19	PMScl 75	Human exosome complex	●	●	●	
A20	Scl70	DNA-topoisomerase I	●		●	
A21	CENP A	Centromere A	●		●	
A22	CENP B	Centromere B	●		●	
A23	POLR3A	RNA polymerase III	●		●	
A24	NOR90	Nucleolar transcription factor 1 (Ubtf1)	●		●	●
A25	Th/To	Ribonuclease P protein subunit 25 (Rpp25)	●		●	
A26	PDGFR-β	Platelet-derived growth factor receptor beta	●		●	
A27	Fibrillarin	U3 RNP - fibrillarin	●		●	
A28	Ro52	TRIM21	●	●	●	●
A29	Ro60	Sjögren's-syndrome-related antigen A (SS-A)	●			●
A30	La	Sjögren's-syndrome-related antigen B (SS-B)	●			●
A31	RNP A	U1 small nuclear ribonucleoprotein A	●		●	●
A32	RNP 68/70	U1 small nuclear ribonucleoprotein 68/70 kDa	●		●	●
A33	RNP C	U1 small nuclear ribonucleoprotein C	●		●	●
A34	SmB	Smith antigen B	●			●
A35	SmD	Smith antigen D	●			●
A36	PCNA	Proliferating cell nuclear antigen	●			●
A37	P0	Ribosomal protein P0	●			●
A38	Ku	Ku (p70/p80)	●	●	●	●
A39	Nucleolin	Nucleolin	●			●
A40	Histons	Histone	●			●
A41	Nucleosome	Nucleosome	●			●
A42	dsDNA	Double-stranded DNA	●			●
A43	M2	Mitochondrial M2 (AMA-M2)	●		●	
A44	DFS70	Dense fine speckled 70 antigen	●			


*Check availability in your country.

● - supplementary antigens, SLE - Systemic lupus erythematosus



Microblot-array for the diagnostics of *Bordetella pertussis* and *Bordetella parapertussis*

Microblot-Array Bordetella kits provide the detailed determination of the presence of specific IgA, IgG, and IgM antibodies to recombinant *Bordetella pertussis* and *Bordetella parapertussis* antigens in human serum or plasma. It can be used for differentiation of postinfection and postvaccination antibodies as well as for differentiation disease stage. It confirms positive or borderline ELISA or agglutination test.



Test Characteristics


Parameters of Microblot-Array Bordetella kits

<u>Pathogen</u>	<u>Diagnostic Sensitivity</u>	<u>Diagnostic Specificity</u>
Microblot-Array Bordetella pertussis IgA	95.4%	100.0%
Microblot-Array Bordetella parapertussis IgA	96.9%	100.0%
Microblot-Array Bordetella pertussis IgG	97.6%	100.0%
Microblot-Array Bordetella parapertussis IgG	97.1%	100.0%
Microblot-Array Bordetella pertussis IgM	95.4%	100.0%
Microblot-Array Bordetella parapertussis IgM	95.8%	100.0%

<u>Spot No.</u>	<u>Antigen</u>	<u>Description</u>	<u>Pathogen</u>
A1	PT	Pertussis toxin (45 kDa) – basic virulence factor, specific only for <i>B. pertussis</i> , the most important pertussis antigen	Bordetella pertussis
A2	FHA	<i>B. pertussis</i> filamentous hemagglutinin – adhesive protein, important immunogen; selected part of the sequence with high specificity	
A3	ACT	Adenylate cyclase toxin (CyaA) – significant virulence factor of <i>B. pertussis</i> with anti-phagocytic activity	
A4	TCF	Tracheal colonization factor – protein produced only by <i>B. pertussis</i> ; adhesin; enabling the microorganism to adhere to mucosal surfaces of respiratory tract and colonize ciliated epithelial cells and phagocytes	
A5	Pertactin	75 kDa; outer membrane protein of virulent <i>B. parapertussis</i> strains	Bordetella parapertussis
A6	FimN	Fimbriae N – adhesin, non-produced by <i>B. pertussis</i>	
A7	EntA	Entericidin A – membrane lipoprotein	

Clinical Data

Laboratory detection of acute infection in a group of patients with clinical diagnosis of pertussis (n= 25 paired samples)






Microblot-Array for the diagnostics of *Borrelia* species and *Anaplasma phagocytophilum*

The kits are optimized for the detection of specific IgG and IgM antibodies to recombinant antigens of *Borrelia* species and *Anaplasma phagocytophilum* (HGA) in human serum, plasma, cerebrospinal or synovial fluid.

Serological diagnostics of borreliosis is difficult due to the large genetic diversity of the species *Borrelia burgdorferi* s.l., possible cross reactivity with unrelated antigens of other microorganisms (p44, OmpA, TpN17 and VCA-p18), and borrelia richness to heat shock proteins. Diagnostics is also complicated due to various individual serological reactivity. The production of antibodies can be extremely slow in the early phase of the disease. On the other hand, the IgG and IgM antibodies can persist for more than ten years. The Microblot-Array *Borrelia* kits help to refine the diagnostics thanks to the high number of antigens present in one single test.



Test characteristics

Parameters of Microblot-Array *Borrelia* IgG (tested on sera)

	Diagnostic Sensitivity	Diagnostic Specificity
Borrelia IgG	97.3% (n = 74)	98.0% (n = 100)
Anaplasma IgG	92.0% (n = 25)	100.0% (n = 30)
Treponema	98.3% (n = 59)	100.0% (n = 30)

Parameters of Microblot-Array *Borrelia* IgM (tested on sera)

	Diagnostic Sensitivity	Diagnostic Specificity
Borrelia IgM	94.6% (n = 56)	95.8% (n = 95)
Anaplasma IgM	95.0% (n = 20)	100.0% (n = 38)
EBV	100.0% (n = 39)	98.0% (n = 51)


Comparative Study

Correlation of results IgG


n = 77	Microblot-Array	ELISA
positive	38	41
negative	33	36
total conformity	92.2 %	

Correlation of results IgM

n = 68	Microblot-Array	ELISA
positive	19	21
negative	40	44
total conformity	90.7 %	




ELISA vs. Microblot-Array IgG



ELISA vs. Microblot-Array IgM


<u>Spot No.</u>	<u>Antigen</u>	<u>Description</u>	<u>Kit</u>	
A1	VlsE Ba	Expressed part of variable major protein-like sequence, significant for IgG antibody response, species-specific antigen		
A2	VlsE Bg			
A3	VlsE Bs			
A4	p83	Main extracellular protein (product of p100 degradation)		
A5	p58	OppA-2 (Oligopeptide permease 2) – membrane transporter, is considered a marker of disseminated stage of Lyme disease		
A6	p41 Ba	Internal flagellin, highly specific antigen of early antibody response		
A7	p41 Bs			
A8	p39	BmpA (glycosaminopeptide receptor) – marker of late IgG antibody response		
A9	OspB	Outer surface protein B, marker of late stage of infection, considered a marker of Lyme arthritis		
A10	OspA Ba	Outer surface protein A, highly specific marker of <i>Borrelia</i> infection in IgG class		Microblot-Array Borrelia IgG
A11	OspA Bg			
A12	OspA Bs			
A13	OspC Ba	Outer surface protein C – main antigen of early antibody response, immunodominant marker of IgM antibody response		Microblot-Array Borrelia IgM
A14	OspC Bg			
A15	OspC Bs			
A16	OspC Bsp			
A17	OspE	Outer surface protein E		
A18	NapA	Neutrophil activating protein A – strong immunogen, main marker of Lyme arthritis pathogenesis		
A19	p17	DbpA (decorin-binding protein A) – outer membrane protein		
A20	p44	<i>Anaplasma phagocytophilum</i> – main marker of HGA antibody response		
A21	OmpA	Outer membrane protein A of <i>Anaplasma phagocytophilum</i> ; peptidoglycan-associated lipoprotein, significant virulence marker		
A22	Asp62	Surface protein – membrane transporter		
A23	TpN17	Highly specific membrane protein of <i>Treponema pallidum</i>		Microblot-Array Borrelia IgG
	VCA-p18	Viral Capsid Antigen p18 – important marker of EBV infection	Microblot-Array Borrelia IgM	

(Ba – *B. afzelii*, Bg – *B. garinii*, Bs – *B. burgdorferi sensu stricto*, Bsp – *B. spielmanii*)



Microblot-Array for the diagnostics of *Chlamydia* species

Microblot-Array Chlamydia are kits designed for the confirmation of positive or cut-off results of samples which were previously screened by ELISA or other serological methods. They serve for the detection of specific IgA and IgG antibodies to recombinant antigens of *Chlamydia* species in human serum or plasma. Thanks to the complex antigen composition they can be used for determination of particular species.



Spot No.	Antigen	Description	Pathogen
A1	MOMP Cp	Dominant major outer membrane protein (species specific) – structural protein; metabolic function	<i>Chlamydia pneumoniae</i>
A2	MOMP1	MOMP isoform, produced by posttranslational modification	
A3	OMP2 Cp	Outer membrane protein (species specific) – structural protein of <i>Chlamydia</i> outer membrane complex	
A4	OMP4	Outer membrane protein	
A5	OMP5	Outer membrane protein	
A6	P54	Immunodominant outer antigen, highly specific to <i>Ch. pneumoniae</i> – sensitive marker for diagnosis of acute infection	
A7	MOMP Ct	Dominant major outer membrane protein (species specific) – structural protein; metabolic function	<i>Chlamydia trachomatis</i>
A8	OMP2 Ct	Outer membrane protein (species specific) – structural protein of <i>Chlamydia trachomatis</i> <i>Chlamydia</i> outer membrane complex	
A9	HSP60	Heat shock protein (GroEL); marker of chronic infection	
A10	MOMP Cps	Dominant major outer membrane protein (species specific) – structural protein; metabolic function	<i>Chlamydia psittaci</i>
A11	OMP2 Cps	Outer membrane protein (species specific) – structural protein of <i>Chlamydia</i> outer membrane complex	

Test characteristics

Parameters of Microblot-Array Chlamydia IgA

	<u>Diagnostic Sensitivity</u>	<u>Diagnostic Specificity</u>
<i>Ch. pneumoniae</i>	94.4% (n = 54)	94.3% (n = 53)
<i>Ch. trachomatis</i>	94.1% (n = 68)	94.6% (n = 50)

Parameters of Microblot-Array Chlamydia IgG


	<u>Diagnostic Sensitivity</u>	<u>Diagnostic Specificity</u>
<i>Ch. pneumoniae</i>	94.6% (n = 111)	96.0% (n = 25)
<i>Ch. trachomatis</i>	98.3% (n = 41)	92.7% (n = 60)

Comparative study

Correlation of results IgG


Ch. pneumoniae

<u>n = 52</u>	<u>Microblot-Array</u>	<u>ELISA</u>
positive	31	32
negative	15	20
total conformity	88.5 %	




Ch. pneumoniae

<u>n = 89</u>	<u>Microblot-Array</u>	<u>BLOT</u>
positive	73	81
negative	7	8
total conformity	89.9 %	




Ch. trachomatis

<u>n = 70</u>	<u>Microblot-Array</u>	<u>ELISA</u>
positive	17	20
negative	47	50
total conformity	91.4%	




Ch. trachomatis

<u>n = 39</u>	<u>Microblot-Array</u>	<u>BLOT</u>
positive	17	20
negative	19	19
total conformity	92.3 %	




■ conformity ■ disagreement



Microblot-Array for the diagnostics of SARS-CoV-2 and other coronaviruses

Microblot-Array COVID-19 kits enable simultaneous detection of multiple SARS-CoV-2 markers (NP, RBD, Spike S1, Spike S2, Spike S1 α -variant, Spike S1 γ -variant, Spike S1 δ -variant, E, ACE2, and PLPro). The kits also contain antigens to exclude cross-reactivities with other endemic coronaviruses (MERS-CoV, SARS-CoV, etc.). The kit contains antigens for the detection of various α , γ , δ mutations. The kits are optimized and validated for detection of IgA, IgG and IgM antibodies in human serum or plasma. They can be used for confirmatory testing, screening, epidemiological studies, identification of donors for convalescent plasma therapy, and other IVD and research applications related to the novel coronavirus.



Spot No.	Antigen	Description	Pathogen
A1	Nucleocapsid NP	A potent immunodominant coronavirus antigen that contains diagnostically important epitopes for the diagnosis of SARS-CoV-2 Sensitive detection of anti-SARS-CoV-2 IgG antibodies	SARS-CoV-2
A2	RBD	Receptor-binding domain of the S1 subunit of the spike (S) protein of SARS-CoV-2 Anti-RBD SARS-CoV-2 antibodies are highly subtype specific and protective The presence of anti-RBD antibodies significantly correlates with the formation of neutralizing antibodies IgA: for monitoring the immune response after a positive PCR reaction; indicator of the onset of the immune response IgM, IgG: detection of antibodies from 2 to 4 weeks after infection	
A3	Spike S1	The S1 subunit of the SARS-CoV-2 spike protein contains a receptor-binding domain (RBD), through which the virus binds to the surface of the host cell Anti-S1 antibodies are highly subtype specific, showing high sensitivity against SARS-CoV-2 and are protective	
A4	Spike S2	S2 subunit of the spike protein SARS-CoV-2 Plays an important role in the fusion of the virus with the cell membrane	
A5	Spike S1 α -variant	British mutation, Spike Glycoprotein S1 (B.1.1.7)	
A6	Spike S1 γ -variant	Brazilian mutation, Spike Glycoprotein S1 (P.1)	
A7	Spike S1 δ -varianta	Indian mutation, Spike Glycoprotein S1 (B1.617.2)	
A8	Envelope protein (E)	The smallest major structural protein Important for different stages of viral infection and replication, important role in the life cycle of the virus	

Spot No.	Antigen	Description	Pathogen
A9	ACE2	Angiotensin Converting Enzyme (transmembrane glycoprotein) A key component of the renin-angiotensin system Expressed in vascular endothelial cells in the heart, kidneys, but also the testes, liver, intestines, lungs and also the brain Involved in the regulation of cardiovascular and renal function	Human receptor
A10	PLpro	Papain-like protease One of the basic SARS-CoV-2 proteins, essential for virus replication; deubiquitination activity Necessary for proteolysis of the viral polyprotein	SARS-CoV-2
A11	MERS-CoV S1	Middle East Respiratory Syndrome Coronavirus S1 protein	
A12	SARS-CoV Np	Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid protein	Other endemic coronaviruses
A13	HCoV 229E Np	Human coronavirus 229E Nucleocapsid protein	
A14	HCoV NL63 Np	Human coronavirus NL63 Nucleocapsid protein	

Test characteristics


Parameters of Microblot-Array COVID-19 kits

	Diagnostic Sensitivity	Diagnostic Specificity
Microblot-Array COVID-19 IgA	98.3% (n = 233)	96.2% (n = 593)
Microblot-Array COVID-19 IgG	98.7% (n = 309)	99.3% (n = 600)
Microblot-Array COVID-19 IgM	97.7% (n = 219)	99.3% (n = 598)


Comparative study

Correlation of results IgG

n = 102	Microblot-Array	BLOT
positive	87	91
negative	4	11
total conformity	93.5 %	




n = 247	Microblot-Array	ELISA
positive	237	236
negative	10	7
total conformity	98.4 %	



Correlation of results IgM

n = 228	Microblot-Array	ELISA
positive	193	193
negative	35	27
total conformity	96.5 %	




■ conformity ■ disagreement



Microblot-Array for the diagnostics of cytomegalovirus infection

The Microblot-Array CMV kit is a new generation kit exhibiting a high diagnostic sensitivity and specificity and enabling quantitative evaluation. It is intended for confirmatory determination of specific antibodies in samples identified as positive or borderline by EIA or other serological tests. It is also intended to determine the presence of specific antibodies against CMV antigens, which allows to distinguish whether the primary infection is in an early or late stage or whether it is a secondary infection or reactivation.



Test characteristics

Parameters of Microblot-Array CMV kits

	Diagnostic Sensitivity	Diagnostic Specificity
Microblot-Array CMV IgG	98.1%	99.9%
Microblot-Array CMV IgM	96.9%	99.1%

Spot No. Antigen Description

Spot No.	Antigen	Description
A1	p150	Tegument protein UL32 A strong immunogen of the late stage of infection (late antigen); it does not develop in the early stage. Detectable in the IgG class in higher titres even in reactivation.
A2	IEA (p72)	Immediate early antigen, capsid protein UL123 Plays a role in the early phase of the replication cycle of human CMV Important function in defence mechanisms against CMV infection
A3	p65	Tegument protein UL83 In the IgM class – one of the markers of the early stage of infection In the IgG class – rather typical for the late stage or infection reactivation
A4	p52	CM2 protein; UL44 In the IgM class – an important marker of the early stage of primary infection In the IgG class – reactivity rather in the late stage, or infection reactivation
A5	p28	Tegument protein UL99 A strong immunogen: it may develop in late stages of infection
A6	gB	Membrane glycoprotein B Antibody response in IgG class – approximately 50–100 days after primary infection

Interpretation of Microblot-Array CMV results


	<u>IgM</u>						<u>IgG</u>					
	p150	IEA (p72)	p65	p52	p28	gB	p150	IEA (p72)	p65	p52	p28	gB
Early primary infection	-	(+)	+	+	-	-	-	(+)	-	-	-	-
Primary infection	(+)	(+)	+	+/-	(+)	-	-	(+)	(+)	(+)	(+)	-
Late primary infection	+	+/-	+/-	+/-	(+)	-	+	(+)	+	+	(+)	(+)
Persistence of infection	-	-	-	-	-	-	+	+/-	+	+	(+)	+
Reactivation	+/-	(+)	+	+	(+)	-	+	(+)	+	+	(+)	+

(+) the marker may or may not be present
 ± weak or unclear reaction

Comparative study


Correlation of results IgG

	<u>Microblot-Array</u>	<u>BLOT</u>
positive	31	31
negative	10	10
total conformity	95.1 %	



BLOT vs. Microblot-Array


	<u>Microblot-Array</u>	<u>ELISA</u>
positive	200	199
negative	50	51
total conformity	96.4 %	



ELISA vs. Microblot-Array


Correlation of results IgM

	<u>Microblot-Array</u>	<u>BLOT</u>
positive	17	17
negative	21	21
total conformity	94.7 %	




BLOT vs. Microblot-Array

	<u>Microblot-Array</u>	<u>ELISA</u>
positive	109	110
negative	146	145
total conformity	93.3 %	




ELISA vs. Microblot-Array

■ conformity ■ disagreement



Microblot-Array for the diagnostics of Epstein-Barr virus

Microblot-Array EBV kits are optimized and validated for detection of IgA, IgG and IgM antibodies in human serum or plasma. The kits are intended for confirmatory determination of specific antibodies in samples that have been identified mainly as positive or borderline by ELISA or other serological tests. Determination of specific class antibodies against EBV antigens is a useful tool for identifying a stage of EBV infection (primary infection, latent chronic infection or reactivation).



Spot No.	Antigen	Description
A1	EBNA-1	Epstein-Barr nuclear antigen 1 IgG: an important diagnostic marker of the late phase or reactivation of the infection IgM: the antibodies are detectable 2–4 months after primary EBV infection, they may also appear during reactivation
A2	EBNA-2	Epstein-Barr nuclear antigen 2 IgG: high antibody titres are present during chronic infection or in the post-acute phase The absence of IgG anti-EBNA-2 antibodies and the presence of anti-EBNA-1 antibodies rules out primary infection
A3	VCA p18	Viral Capsid Antigen p18; IgA: marker of primary infection; high titres persist in patients with nasopharyngeal carcinoma IgM: marker of primary infection; they may also be present during infection reactivation IgG: an important marker of the late phase of the infection, antibodies do not occur in primary infections
A4	VCA p23	Viral Capsid Antigen p23 Antibodies against this antigen can be detected during all phases of the infection (both IgG and IgM), they persist in the body for a long time
A5	EA-D p54	Early Antigen Diffuse p54; BMRF1 IgA: produced during primary infection; high titres during reactivation; high titres persist in patients with nasopharyngeal carcinoma An additional marker of acute EBV infection, detectable even in the latent phase of primary infection (both IgG and IgM)
A6	EA-D p138	Early Antigen Diffuse p138 IgA: produced during primary infection; high titres during reactivation; high titres persist in patients with nasopharyngeal carcinoma An additional marker of acute EBV infection, detectable even in the latent phase of primary infection (both IgG and IgM)
A7	EA-R	Early Antigen Restricted protein p85; IgG: antibodies usually occur at a later stage; they are practically absent during the acute phase except in children; high levels in patients with reactivation or in immunocompromised patients
A8	Rta	Replication and transcription Activator (BRLF1); A very early antigen IgG: a potential diagnostic marker of a nasopharyngeal carcinoma

Spot No.	Antigen	Description
A9	ZEBRA	Z Epstein-Barr replication activator protein; Trans-activator protein BZLF1 IgM: it is a very early indicator of an acute infection IgG: it is an early stage marker but it is also detectable during the late stages of the infection Serological marker of EBV reactivation, marker of EBV-associated diseases
A10	gp85	Probable membrane antigen gp85 (BDLF3);
A11	gp350	Epstein-Barr virus envelope glycoprotein gp350 (BLLF1); IgM: high titres in patients with infectious mononucleosis IgG: the titre increases only a few months after the primary infection Specific immune response for EBV-associated diseases
A12	LMP1	Latent membrane protein 1 Frequent in latent infections Linked to EBV-associated malignancies (nasopharyngeal carcinoma)



Test characteristics

Parameters of Microblot-Array EBV kits



	<u>Diagnostic Sensitivity</u>	<u>Diagnostic Specificity</u>
Microblot-Array EBV IgA	98.9% (n = 167)	96.7% (n = 70)
Microblot-Array EBV IgG	98.8% (n = 167)	96.9% (n = 70)
Microblot-Array EBV IgM	96.4% (n = 61)	89.3% (n = 60)

Comparative study

POSITIVE SAMPLES




NEGATIVE SAMPLES





Microblot-Array for the diagnostics of *Helicobacter pylori* infection

The kits are optimized and validated for the detection of IgA and IgG antibodies against recombinant antigens *Helicobacter pylori* in human serum. For confirmation of ELISA positive or ambiguous results.



Test Characteristics

Parameters of Microblot-Array *Helicobacter pylori* kit


	Diagnostic Sensitivity	Diagnostic Specificity
Microblot-Array <i>Helicobacter</i> IgA	96.5%	99.1%
Microblot-Array <i>Helicobacter</i> IgG	97.4%	99.0%

Spot No.	Antigen	Description
A1	CagA, p120	Cytotoxin associated gene A, highly specific, virulence factor
A2	VacA, p87	Vacuolating cytotoxin A, highly specific, virulence factor
A3	UreA, p29	Light subunit of urease, specific, virulence factor
A4	NAP	Neutrophil-activating protein, virulence factor, potential biomarker of gastritis
A5	HpaA	<i>Helicobacter pylori</i> adhesin A, surface lipoprotein, potential biomarker of gastritis and gastric ulcer
A6	HcpC	<i>Helicobacter</i> cystein-rich protein, virulence factor
A7	GroEL	Chaperonin, heat shock protein (Hsp 60), virulence factor, considered as a marker of chronic infection



Microblot-Array for the diagnostics of *Herpes simplex virus* infection

The Microblot-Array HSV kit is a new generation kit exhibiting a high diagnostic sensitivity and specificity and enabling quantitative evaluation. It is intended for confirmatory determination of specific antibodies in samples identified as positive or borderline by EIA or other serological tests. It is also intended to determine the presence of specific antibodies against HSV 1+2 antigens, which allows to distinguish whether the primary infection is in an early or late stage or whether it is a secondary infection or reactivation.



Test Characteristics

Parameters of Microblot-Array HSV kits


	Diagnostic Sensitivity	Diagnostic Specificity
Microblot-Array HSV 1+2 IgG	99.9%	97.5%
Microblot-Array HSV 1+2 IgM	95.0%	99.4%

Spot No.	Antigen	Description
A1	HSV 1+2	Native HSV-1 and HSV-2 antigen
A2	gC-1	Glycoprotein C-1 specific for <i>Herpes simplex 1 virus</i> ;
A3	gC-2	Glycoprotein C-2 specific for <i>Herpes simplex 2 virus</i> ; Early antibody production
A4	gD-1	Glycoprotein D-1 specific for <i>Herpes simplex 1 virus</i> ;
A5	gD-2	Glycoprotein D-2 specific for <i>Herpes simplex 2 virus</i> serves to capture and entry of the virus into a potential host cell; stimulates high production of neutralizing antibodies, high similarity between HSV-1 and -2
A6	gG-1	Glycoprotein G-1 specific for <i>Herpes simplex 1 virus</i> ;
A7	gG-2	Glycoprotein G-2 specific for <i>Herpes simplex 2 virus</i> Appropriate for differentiating between HSV-1 and -2 infection In the IgG class – indications of previous or probably latent infection; antibodies are formed only in the convalescent phase, they have been found also in patients with reactivation of infection In the IgM class – antibodies are produced only in the convalescent phase



Microblot-array for the diagnostics of *Mycoplasma* infection

Microblot-Array Mycoplasma kits are used for the detection of specific IgA and IgG antibodies against recombinant antigens of *Mycoplasma pneumoniae* in human serum or plasma. Intended use is for confirmation of EIA ambiguous or positive results.




Test Characteristics

Parameters of Microblot-Array *Mycoplasma pneumoniae*


	Diagnostic Sensitivity	Diagnostic Specificity
Microblot-Array Mycoplasma IgA	97.1%	99.3%
Microblot-Array Mycoplasma IgG	95.7%	99.0%
Microblot-Array Mycoplasma IgM	98.9%	99.3%

Spot No.	Antigen	Description
A1	P1	Adhesin; the most important protein, a major virulence factor
A2	p30	Cytadhesin p30; the second most important protein, a major virulence factor
A3	p116	Adhesin, a major virulence factor
A4	p65	Surface protein; proline-rich P65 protein
A5	HMW3	Cytadherence high molecular weigh 3; adhesion-promoting protein
A6	Mgp3	Adhesion-promoting protein



Microblot-Array for the diagnostics of *Yersinia* infection

The kits are suitable for the detailed determination of anti-*Yersinia* species specific IgA and IgG antibodies in human serum or plasma. Confirmation of ELISA positive or ambiguous results.



Test Characteristics

Parameters of Microblot-Array *Yersinia* sp.

	Diagnostic Sensitivity	Diagnostic Specificity
Microblot-Array <i>Yersinia</i> IgA	96.1%	99.9%
Microblot-Array <i>Yersinia</i> IgG	95.5%	99.9%

Spot No.	Antigen	Description
A1	YopB	<i>Yersinia</i> outer protein, transmembrane protein
A2	YopD	<i>Yersinia</i> outer protein, transmembrane protein
A3	YopM	<i>Yersinia</i> outer protein
A4	YopN	<i>Yersinia</i> outer protein
A5	LcrV	Low calcium response Virulence, important for YopD a YopB secretion
A6	Ail	Attachment-invasion locus protein early phase, involved in the adhesion and invasion process, allows <i>Yersinia</i> to survive outside the host cell, a significant virulence factor
A7	Invasin	Surface adhesin binding to β 1 integrins on surface of target cells; important in the first stage of infection, a virulence factor
A8	YscM-Y.Ent	Yop proteins translocation protein M

Microblot-Array kits in development

Gastrointestinal diseases

<u>Kit</u>	<u>Antigens/parameters</u>	<u>Availability</u>
Microblot-Array Autoimmune gastroenteritis IgA, IgG	ASCA, DAG, tTG, IF, APCA, MPO	2023
Microblot-Array Gastro panel IgA, IgG	Helicobacter pylori, Yersinia enterocolitica, Autoimmune gastroenteritis	In development

Herpetic infections

<u>Kit</u>	<u>Antigens/parameters</u>	<u>Availability</u>
Microblot-Array Herpetic infections panel IgG, IgM	EBV, CMV, HSV, VZV, HHV-6	In development

Liver-Kidney diseases

<u>Kit</u>	<u>Parameters</u>	<u>Availability</u>
Microblot-Array Liver-Kidney profile	3E (BPO), M2, Sp100, PML, gp210, LKM-1, LC-1, SLA/LP, Ro52, ASGPR, Nup62, OGDC-E2, PDC-E2	2023

Atypical respirations

<u>Kit</u>	<u>Parameters</u>	<u>Availability</u>
Microblot-Array Atypical respirations panel IgA, IgG, IgM	Mycoplasma pneumoniae, Bordetella sp., Chlamydia pneumoniae, Legionella pneumophila	In development

Autoimmune neurological diseases

<u>Kit</u>	<u>Antigens</u>	<u>Availability</u>
Microblot-Array Paraneoplastic syndrome	Amphysin, CV2, GAD65, Hu, MA1, MA2, MAG, Recoverin, Ri, SOX1, Titin, Tr, Yo, ZIC4, AChR, MusK, Aquaporin-4	In development
Microblot-Array Limbic encephalitis	LGI1, CASPR2, NMDAR, AMPA1/2, GABA1/2	In development

Anti-neutrophil cytoplasm antibodies

<u>Kit</u>	<u>Antigens</u>	<u>Availability</u>
Microblot-Array ANCA	PR3, MPO, GMB*	In development

*Other antigens will be added later.

Tropical diseases

<u>Kit</u>	<u>Parameters</u>	<u>Availability</u>
Microblot-Array Tropical diseases panel	Dengue, Chikungunya, Zika, West Nile Fever, Plasmodium, Rickettsia, Leptospira	In development

Vector transmitted infections

<u>Kit</u>	<u>Parameters</u>	<u>Availability</u>
Microblot-Array Vector transmitted infections panel	Rickettsia, Babesia, Anaplasma phagocytophilum, Neoehrlichia (Candidatus Neoehrlichia mikurensis), TBEV, Borrelia burgdorferi, Francisella tularensis, Q-fever (Coxiella burnetti)*	In development

*Kit composition will be more specified later

Endocrine antibodies

<u>Kit</u>	<u>Antigens/parameters</u>	<u>Availability</u>
Microblot-Array Thyroid disease	TPO, TSH, TG	In development
Microblot-Array Diabetes mellitus Type I	ICA, IAA, IA-2, GAD, ZnT8	In development
Microblot-Array Endocrine antibodies	Thyroid disease, Diabetes mellitus Type I	In development

TORCH

<u>Kit</u>	<u>Parameters</u>	<u>Availability</u>
Microblot-Array TORCH panel	Toxoplasma, Rubella, CMV, HSV 1+2	In development

* Expected availability may change, there may be a slight changes in antigenic composition. Status „In development“ does not guarantee final launch of the product.

Ordering information



All kits are CE and IVD certified.

Kits

AUTOIMMUNITY

<u>Code</u>	<u>Products</u>	<u>No. of tests</u>
ANApMA96	Microblot-Array ANA plus*	96

*Check availability in your country.

INFECTIOUS SEROLOGY

<u>Code</u>	<u>Products</u>	<u>No. of tests</u>
BpAMA48	Microblot-Array Bordetella IgA	48
BpGMA48	Microblot-Array Bordetella IgG	48
BpMMA48	Microblot-Array Bordetella IgM	48
BGMA096	Microblot-Array Borrelia IgG	96
BMMA096	Microblot-Array Borrelia IgM	96
CAMA096	Microblot-Array Chlamydia IgA	96
CGMA096	Microblot-Array Chlamydia IgG	96
CoVAMA96	Microblot-Array COVID-19 IgA	96
CoVGMA96	Microblot-Array COVID-19 IgG	96
CoVMMMA96	Microblot-Array COVID-19 IgM	96
CMGMA48	Microblot-Array CMV IgG	48
CMMMA48	Microblot-Array CMV IgM	48
EBAMA96	Microblot-Array EBV IgA	96
EBGMA96	Microblot-Array EBV IgG	96
EBMMA96	Microblot-Array EBV IgM	96
HpAMA48	Microblot-Array Helicobacter IgA	48
HpGMA48	Microblot-Array Helicobacter IgG	48
HSGMA48	Microblot-Array HSV 1+2 IgG	48
HSMMA48	Microblot-Array HSV 1+2 IgM	48
MyAMA48	Microblot-Array Mycoplasma IgA	48
MyGMA48	Microblot-Array Mycoplasma IgG	48
MyMMA48	Microblot-Array Mycoplasma IgM	48

<u>Code</u>	<u>Products</u>	<u>No. of tests</u>
YAMA048	Microblot-Array Yersinia IgA	48
YGMA048	Microblot-Array Yersinia IgG	48

Hardware a Software

<u>Code</u>	<u>Products</u>
ARCXIX096	Microblot-Array Reader (Array Reader C-series) + Software

Components

<u>Code</u>	<u>Products</u>
000008262	Universal Solution (300 ml)*

*In the case of automated processing, an additional universal solution is required because of the dead volumes of the instruments. We recommend 2 extra bottles/kit (when running one plate per week). Please contact our sales representatives for more information.



FOLLOW US

BIOVENDOR.GROUP



TestLine Clinical Diagnostics s.r.o.

Křižíkova 68, 612 00 Brno, Czech Republic

+420 549 121 259 | +420 541 243 390

sales@testlinecd.com

www.testlinecd.com



Company is certified to the quality management system standards ISO 9001 and ISO 13485 for in vitro diagnostics.